Companies
Comprehensive database of innovative Biophama companies in Korea
BQURA Company Database
Find out most innovative Korean Biopharma companies
Abion
BiotechABION Inc. operates as a pharmaceutical biotech company in South Korea and internationally. The company develops anticancer therapeutic drugs, such as ABN401, a tyrosine kinase inhibitor that is in Phase II clinical trials for treating non-small cell lung cancer, as well as in Phase I clinical trial for breast cancer; ABN501, a human monoclonal antibody that targets claudin 3 for treating solid cancers; ABN201, an antibody cytokine fusion protein to treat solid cancers; and ABN101, a dry powder inhaler as a prophylactic treatment for various respiratory viruses. It is also developing ABN701 for SEBI infectious diseases; and ABN901, ABN902, and ABN903 for infectious diseases related to biological disasters. Abion Inc. was founded in 2007 and is based in Seoul, South Korea.
EnCell
CDMOENCell is dedicated to improving patients' quality of life and overcoming diseases through the development of advanced cell and gene therapies. The company offers comprehensive CDMO services, enabling clients to effectively develop and produce their products by leveraging ENCell's expertise, technology, and state-of-the-art facilities. Committed to the highest quality standards, ENCell maintains a rigorous quality assurance system to ensure product efficacy and safety, adhering to the latest regulations. The company fosters close collaboration with clients, providing flexible solutions to achieve project success.
Organoid Science
BiotechOrganoid Sciences is dedicated to developing next-generation regenerative cell therapies by leveraging organoids that contain a high concentration of organ-specific adult stem cells, offering exceptional regenerative capabilities when transplanted into damaged tissues. Additionally, organoids derived from patient tissues closely mimic human physiology, serving as a platform for new drug development and the discovery of novel substances.
LIVEOME
BiotechFounded in 2021, LIVEOME Co., Ltd. is a South Korean biotechnology company specializing in the development of next-generation microbiome therapeutics aimed at treating incurable diseases. As a subsidiary of the biopharmaceutical company Medy-Tox Inc., LIVEOME focuses on creating disease-specific live biotherapeutic products (LBP) to address conditions such as Crohn's disease and ulcerative colitis.
HEM Pharma
BiotechFounded in January 2017, HEM Pharma Inc. is a South Korean biotechnology company specializing in microbiome-based solutions. The company focuses on developing probiotics, antibiotics, and other products aimed at personalized healthcare and live biotherapeutic products (LBP). HEM Pharma conducts research to understand the relationship between diseases and the human body's microbiota, providing optimal solutions for individuals.
NEX-I
BiotechFounded in 2021, NEX-I Co., Ltd. is a South Korean biotechnology company specializing in the development of next-generation immunotherapeutics aimed at enhancing the efficacy of cancer treatments. The company's platform designs assessment tools to evaluate the target efficacy of cancer immunotherapy, striving to improve the quality of life for patients and their families by controlling tumor growth through the activation of both dendritic cells and cytolytic T cells.
IMbiologics
BiotechEstablished in August 2020, IMBiologics Co., Ltd. is a South Korean biotechnology company specializing in the development of innovative immunomodulatory antibody therapeutics. The company's mission is to restore physiological balance, or homeostasis, in patients by developing novel biologics that modulate immune responses.
SML Biopharm
BiotechEstablished in 2021 by CEO Jae-Hwan Nam, SML Biopharm is an innovative South Korean biotechnology company focusing on the research and development of mRNA vaccines and therapeutics. The company combines a cutting-edge mRNA platform with an advanced lipid nanoparticle (LNP) drug delivery system to develop next-generation cancer vaccines and treatments for various diseases.
DuchemBio
PharmaEstablished in 2002, DuChemBio Co., Ltd. is a leading South Korean company specializing in the development, production, and sale of radiopharmaceuticals for cancer diagnosis and treatment. The company focuses on providing advanced diagnostic solutions for neurological disorders and various types of cancers.
rnagene
BiotechRNAgene Inc., established in 2018 and based in Seoul, South Korea, is a pioneering biotechnology company specializing in the development of mRNA-based therapeutics. The company has developed its proprietary mRNA-LNP platform and focuses on creating innovative solutions for various medical needs, including prophylactic and therapeutic vaccines, immuno-oncologic drugs, and treatments for infectious diseases
APITbio
BiotechFounded in 2018, APITBIO Co., Ltd. is a South Korean biotechnology company specializing in the development of innovative antibody-based therapeutics, particularly targeting cancer and infectious diseases. The company's mission is to address unmet medical needs by advancing novel biologics through comprehensive research and development processes, encompassing antibody screening, discovery, optimization, and production.
PROTEINA
BiotechEstablished in 2015, PROTEINA Co., Ltd. is a South Korean biotechnology company specializing in the analysis of protein-protein interactions (PPIs) to advance disease diagnosis and drug discovery. The company has developed a proprietary platform that enables quantitative measurement of PPIs at the single-molecule level, facilitating the identification of novel biomarkers and therapeutic targets.